US 12,134,605 B2
Substituted 1,2,4-triazoles and methods of use
Glen N Barber, Miami, FL (US)
Assigned to StingInn, LLC, Miami, FL (US)
Filed by STINGINN LLC, Miami, FL (US)
Filed on Dec. 18, 2020, as Appl. No. 17/127,797.
Application 17/127,797 is a continuation in part of application No. PCT/US2020/065756, filed on Dec. 17, 2020.
Claims priority of provisional application 63/126,517, filed on Dec. 16, 2020.
Claims priority of provisional application 62/949,511, filed on Dec. 18, 2019.
Prior Publication US 2021/0188786 A1, Jun. 24, 2021
Int. Cl. C07D 249/12 (2006.01); A01N 43/82 (2006.01); C07D 271/06 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 417/12 (2006.01)
CPC C07D 249/12 (2013.01) [A01N 43/82 (2013.01); C07D 271/06 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 417/12 (2013.01)] 6 Claims
 
1. A pharmaceutical composition comprising a therapeutically effective amount of a compound for activating the stimulator of interferon genes (STING) and a pharmaceutically acceptable carrier, wherein the compound is N-(1-(3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl)ethyl)benzenesulfonamide, a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof.